Loading...
•
Jun 30
Evolus Q2 2025 Earnings Report
Evolus reported its second quarter 2025 financial results, highlighting global net revenue growth, the successful launch of Evolysse™, and strategic cost structure optimization.
Key Takeaways
Evolus reported global net revenue of $69.4 million for Q2 2025, a 4% increase from Q2 2024, driven by the successful launch of Evolysse™ and strong international market performance, despite a softened U.S. toxin demand. The company also took decisive action to optimize its cost structure, aiming for meaningful profitability in Q4 2025.
Global net revenue reached $69.4 million in Q2 2025, a 4% increase year-over-year, despite a decrease in overall U.S. aesthetic procedures.
The launch of Evolysse™ contributed $9.7 million in revenue for Q2 2025, marking the strongest filler launch quarter in over a decade.
Evolus maintained a 14% market share in the U.S. toxin market through the first half of 2025, with Jeuveau® continuing to outperform the market.
Strategic cost structure optimization is expected to yield at least $25 million in non-GAAP operating expense savings for 2025, with the company anticipating meaningful profitability in Q4 2025 and annual profitability starting in 2026.
Evolus
Evolus
Evolus Revenue by Segment
Revenue by Segment
Product Revenue, Net Revenue
CapyFin.comService Revenue
CapyFin.com Forward Guidance
Evolus has reset its 2025 net revenue guidance to $295 million to $305 million and rebased 2025 non-GAAP operating expenses to $208 million to $213 million. The company expects to achieve meaningful profitability in Q4 2025 and annual profitability beginning in 2026, while maintaining its long-term goal of $700 million total net revenue and 20% non-GAAP operating income margin by 2028.
Positive Outlook
- Expects total net revenues for full-year 2025 to be between $295 million and $305 million, representing 11% to 15% growth over 2024.
- Increases Evolysse™ injectable HA gels contribution to 10% to 12% of total revenue for the full-year 2025.
- Anticipates achieving meaningful profitability in Q4 2025 and annual profitability beginning in 2026.
- Strategic cost structure optimization is expected to yield at least $25 million in non-GAAP operating expense savings for 2025.
- Maintains projected total net revenue goal of $700 million and non-GAAP operating income margin of 20% by 2028.
Challenges Ahead
- The recently announced trade deal with the European Union will subject Evolysse™ to a 15% tariff starting August 7, though expected to have minimal impact.
- A broader European launch of Estyme® is now planned for Q1 2026, a slight delay from previous expectations.
- The company is actively monitoring developments and remains focused on mitigating any potential future exposure to tariffs.
- No specific negative forward guidance points were explicitly stated beyond the tariff and launch timing adjustments.
- The summary does not contain enough distinct negative points to fulfill the 5-bullet requirement without repetition or speculation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income